(Q24289204)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Microtubules as a target for anticancer drugs

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Adverse effects of androgen deprivation therapy and strategies to mitigate them.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Intermittent versus continuous androgen deprivation in prostate cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

The burden of prostate cancer in Asian nations

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

International variation in prostate cancer incidence and mortality rates.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Early effects of pharmacological androgen deprivation in human prostate cancer.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

27 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV245

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV245

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV245

Fatigue in patients with prostate cancer receiving hormone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV245

Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV245

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV245

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV245

Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV245

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511224

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

29 November 2018

1 reference

12 December 2020

Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eu

1 reference

12 December 2020

Taxanes: still a major weapon in the armamentarium against prostate cancer

1 reference

12 December 2020

Who dies from prostate cancer?

1 reference

12 December 2020

Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study

1 reference

12 December 2020

Bcl2 is the guardian of microtubule integrity

1 reference

12 December 2020

Identifiers

DOI

10.1093/ANNONC/MDV245

1 reference

release_ul2ja34655fllehw2fla2zd5im

731251

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ul2ja34655fllehw2fla2zd5im

24 November 2022

mapped directly with Wikidata item

731251

1 reference

1 reference

1 reference